奥马珠单抗治疗慢性荨麻疹的多国药物生存研究及停药预测因素
该国际多中心队列研究纳入10国14个荨麻疹参考卓越中心的2325例慢性荨麻疹患者,评估奥马珠单抗药物生存率及停药原因与预测因素。结果显示1年生存率76%降至7年39%,中位生存3.3年,主要停药原因为疾病控制良好(65%),快速治疗反应与高停药率相关,而自发风团和更高剂量可及性与低无效率停药相关。
要点
- 奥马珠单抗治疗慢性荨麻疹在临床实践中有效且安全,疾病控制良好是主要停药原因。
- 快速治疗反应与因疾病控制良好而停药的风险增加相关(HR 1.45)。
- 自发风团和更高剂量可及性与因无效而停药的风险降低相关。
核心结论
- 奥马珠单抗治疗慢性荨麻疹在临床实践中有效且安全,疾病控制良好是主要停药原因。
研究设计与样本
- 国际多中心队列研究,纳入10国14个荨麻疹参考卓越中心的2325例曾接受奥马珠单抗治疗的慢性荨麻疹患者。
主要发现
- 总体奥马珠单抗生存率从1年76%降至7年39%,中位生存时间3.3年(95%CI 2.9-4.0)。
- 停药原因中疾病控制良好占576例(65%),无效占164例(18%),不良反应占31例(4%)。
- 快速治疗反应与因疾病控制良好而停药的风险增加相关(HR 1.45,95%CI 1.20-1.75)。
- 病程超过2年与因疾病控制良好而停药的风险降低相关(HR 0.81,95%CI 0.67-0.98)。
- 起始奥马珠单抗时免疫抑制联合治疗和自身免疫性疾病与因无效而停药的风险增加相关(HR 1.65,95%CI 1.12-2.42)。
临床怎么用
- 奥马珠单抗治疗慢性荨麻疹的生存数据可指导患者和医生的临床决策及期望管理。
- 对完全应答者可能需要识别慢性荨麻疹缓解的生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences. Furthermore, little is known about the reasons and potential predictors for omalizumab discontinuation. OBJECTIVE: To investigate omalizumab drug survival as well as reasons and potential predictors for discontinuation in a large, diverse population. DESIGN, SETTING, AND PARTICIPANTS: This international multicenter cohort study was conducted at 14 Urticaria Centers of Reference and Excellence in 10 countries, including all patients with chronic urticaria from these centers who were ever treated with omalizumab. MAIN OUTCOMES AND MEASURES: Drug survival analysis was performed to assess time to discontinuation. Patient characteristics and treatment protocols were investigated by Cox regression analysis to identify potential predictors for omalizumab discontinuation. RESULTS: In 2325 patients with chronic urticaria who started omalizumab between June 2009 and July 2022, the mean (SD) age of the cohort was 42 (6) years, and 1650 participants (71%) were female. Overall omalizumab survival rates decreased from 76% to 39% after 1 to 7 years, respectively (median survival time, 3.3 [95 % CI, 2.9-4.0] years), primarily due to discontinuation from well-controlled disease in 576 patients (65%). Ineffectiveness and adverse effects were reasons for discontinuation in a far smaller proportion of patients, totaling 164 patients (18%) and 31 patients (4%), respectively. Fast treatment response was associated with higher rates of omalizumab discontinuation due to well-controlled disease (hazard ratio, 1.45 [95% CI, 1.20-1.75]), and disease duration of more than 2 years was associated with lower rates of discontinuation due to well-controlled disease (HR, 0.81 [95% CI, 0.67-0.98]). Immunosuppressive cotreatment at the start of omalizumab and autoimmune disease was associated with a higher risk for discontinuation due to ineffectiveness (HR, 1.65 [95% CI, 1.12-2.42]). The presence of spontaneous wheals (HR, 0.62 [95% CI, 0.41-0.93]) and access to higher dosages (HR, 0.40 [95% CI, 0.27-0.58) were both associated with a lower risk for discontinuation of omalizumab due to ineffectiveness. CONCLUSION AND RELEVANCE: This multinational omalizumab drug survival cohort study demonstrated that treatment of chronic urticaria with omalizumab in a clinical setting is effective and safe, and well-controlled disease is the main reason for treatment discontinuation. These findings on omalizumab drug survival rates and reasons and potential predictors for discontinuation may guide patients and physicians in clinical decision-making and expectation management. These results may call for the identification of biomarkers for chronic urticaria remission in complete responders to omalizumab treatment.
引用
- Soegiharto R, Alizadeh Aghdam M, Sørensen JA, et al. Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation. JAMA Dermatol. 2024. PMID: 39018068. doi:10.1001/jamadermatol.2024.2056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。